A detailed history of Td Asset Management Inc transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Td Asset Management Inc holds 152,684 shares of SWTX stock, worth $5.72 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
152,684
Previous 173,284 11.89%
Holding current value
$5.72 Million
Previous $6.53 Million 25.07%
% of portfolio
0.0%
Previous 0.01%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$32.04 - $42.76 $660,024 - $880,856
-20,600 Reduced 11.89%
152,684 $4.89 Million
Q2 2024

Aug 02, 2024

SELL
$36.06 - $47.62 $2.9 Million - $3.83 Million
-80,348 Reduced 31.68%
173,284 $6.53 Million
Q1 2024

May 08, 2024

BUY
$36.5 - $52.5 $2.64 Million - $3.79 Million
72,200 Added 39.79%
253,632 $12.5 Million
Q4 2023

Feb 12, 2024

BUY
$18.94 - $37.24 $806,844 - $1.59 Million
42,600 Added 30.68%
181,432 $6.62 Million
Q3 2023

Oct 27, 2023

BUY
$23.12 - $31.38 $1.76 Million - $2.39 Million
76,316 Added 122.07%
138,832 $3.21 Million
Q2 2023

Aug 09, 2023

BUY
$23.15 - $32.71 $1.03 Million - $1.45 Million
44,400 Added 245.09%
62,516 $1.64 Million
Q1 2023

May 10, 2023

BUY
$24.97 - $34.05 $62,425 - $85,125
2,500 Added 16.01%
18,116 $466,000
Q2 2022

Aug 04, 2022

SELL
$18.36 - $60.07 $106,488 - $348,406
-5,800 Reduced 27.08%
15,616 $384,000
Q1 2021

May 14, 2021

BUY
$65.1 - $93.59 $128,897 - $185,308
1,980 Added 10.19%
21,416 $1.58 Million
Q4 2020

Feb 16, 2021

BUY
$48.36 - $77.92 $939,924 - $1.51 Million
19,436 New
19,436 $1.41 Million

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.34B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.